China Medical University Hospital (Taiwan) and Shine-On Biomedical Co. developed SOB100, the world's first HLA-G targeted ...

MEDSIR announces positive results from TUXEDO-3 trial of patritumab deruxtecan in patients with active brain metastases and leptomeningeal disease: Chicago Monday, June 9, 2025, 1 ...

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe PRINCETON, N.J., ...

Industry experts gathered at the Outsourcing in Clinical Trials East Coast 2025 conference to discuss artificial intelligence ...

LOS ANGELES, June 9, 2025 /PRNewswire/ — TORL BioTherapeutics LLC (TORL), a clinical-stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the ...

While the company is showing early signs of recovery and margin improvement, a high valuation means risks remain.

An experimental drug empowered by artificial intelligence to identify a novel therapeutic target for a severe lung disease ...

Humacyte markets Symvess for the treatment of extremity vascular trauma. Read why HUMA stock is a Sell but can see its ...

Psychedelics research gains support from the Trump administration for treating PTSD and mental health conditions, with Veterans Affairs exploring treatments that show promise in clinical trials.

Research suggests women with high breast cancer risk and menopausal symptoms could benefit from Duavee, which reduced breast ...

2017-010 Natural History Study Of The Development Of Type 1 Diabetes (Trialnet TN01) Blood draw to determine if a patient may be a risk factor for patients with a family history of Type 1 Diabetes.

New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...